High Producer Haplotype (CAG) of -863C/A, -308G/A and -238G/A Polymorphisms in the Promoter Region of TNF-α Gene Associate with Enhanced Apoptosis of Lymphocytes in HIV-1 Subtype C Infected Individuals from North India
Introduction The natural history of HIV-1 infection and its progression towards AIDS vary considerably among individuals. Host genetic factors may be one of the possible reasons for variable HIV-1 disease progression. Single nucleotide polymorphisms (SNPs) in the promoter region of TNF-α gene can influence its production. The aim of the present study was to determine the association of functional TNF-α SNPs and its associated parameters related to apoptosis that may influence the rate of HIV-1 disease progression. Methods Therapy naive, 100 HIV slow progressors (SPs), 100 HIV fast progressors (FPs), 50 HIV exposed but seronegative individuals (ESNs) and 260 healthy controls from same ethnic origin were recruited. Genotyping of TNF-α variants (？863C/A, -308G/A and -238G/A) was done using PCR-RFLP. CD4 counts were determined by flow cytometry. Plasma viral load was estimated by COBAS AMPLICOR HIV-1 monitor test. Plasma TNF-α concentration was estimated by Human CBA Th1/Th2 cytokine kit. The lymphocyte mitochondrial membrane potential was measured by JC-1 dye by flow cytometry. Results Genotype and allele frequency of TNF-α -238G/A and -863C/A was not significantly different in HIV-1-infected patients when compared to controls, while that of TNF-α -308G/A variant (high TNF-α producer) was significantly higher in FPs compared to SPs (p<0.01, OR = 3.43). Haplotype analyses also showed that carriers of high TNF-α producing haplotype CAG was significantly more common among FPs compared to SPs (p<0.01, OR = 3). The circulating TNF-α levels in blood also correlated well with genotypes. The lymphocyte mitochondrial membrane potential of FPs having CAG haplotype was significantly low as compared to wild type (CGG) haplotype (417±22 vs 571±28, p<0.01). Conclusion High producer haplotype, CAG of TNF-α gene associates with enhanced apoptosis of lymphocytes in HIV-1 infected individuals, hence faster progression to AIDS. However, further functional studies are needed to confirm this association and this knowledge may help clinicians to better understand the disease outcome.
References
[1]
Telenti A, Carrington M (2008) Host factors associated with outcome from primary human immunodeficiency virus-1 infection. Curr Opin HIV AIDS 3: 28–35. doi: 10.1097/coh.0b013e3282f18ac0
[2]
Deghaide NH, Rodrigues Mde L, Castelli EC, Mendes-Junior CT, Figueiredo JF, et al. (2009) Tumor necrosis factor region polymorphisms are associated with AIDS and with cytomegalovirus retinitis. AIDS 23: 1641–1647. doi: 10.1097/qad.0b013e32832e5591
[3]
Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW (1997) Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A 94: 3195–3199. doi: 10.1073/pnas.94.7.3195
[4]
Heijmans BT, Westendorp RG, Droog S, Kluft C, Knook DL, et al. (2002) Association of the tumour necrosis factor alpha -308G/A polymorphism with the risk of diabetes in an elderly population-based cohort. Genes Immun 3: 225–228. doi: 10.1038/sj.gene.6363859
[5]
Kim YJ, Lee HS, Yoon JH, Kim CY, Park MH, et al. (2003) Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection. Hum Mol Genet 12: 2541–2546. doi: 10.1093/hmg/ddg262
[6]
Herbein G, O’Brien WA (2000) Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med 223: 241–257. doi: 10.1046/j.1525-1373.2000.22335.x
Silva MM, Simoes RT, Castelli EC, Mendes-Junior CT, Deghaide NH, et al. (2010) TNF microsatellite alleles may confer protection against the development of lipodystrophy syndrome in Brazilian HIV patients. Int J Immunogenet 37: 379–385. doi: 10.1111/j.1744-313x.2010.00937.x
[9]
Maxwell JR, Potter C, Hyrich KL, Barton A, Worthington J, et al. (2008) Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 17: 3532–3538. doi: 10.1093/hmg/ddn245
[10]
Nolan D, Moore C, Castley A, Sayer D, Mamotte C, et al. (2003) Tumour necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS 17: 121–123. doi: 10.1097/00002030-200301030-00017
[11]
Delgado JC, Leung JY, Baena A, Clavijo OP, Vittinghoff E, et al. (2003) The -1030/？862-linked TNF promoter single-nucleotide polymorphisms are associated with the inability to control HIV-1 viremia. Immunogenetics 55: 497–501. doi: 10.1007/s00251-003-0604-7
[12]
Knuchel MC, Spira TJ, Neumann AU, Xiao L, Rudolph DL, et al. (1998) Analysis of a biallelic polymorphism in the tumor necrosis factor alpha promoter and HIV type 1 disease progression. AIDS Res Hum Retroviruses 14: 305–309. doi: 10.1089/aid.1998.14.305
[13]
Erikstrup C, Kallestrup P, Zinyama-Gutsire RB, Gomo E, Butterworth AE, et al. (2007) Reduced mortality and CD4 cell loss among carriers of the interleukin-10–1082G allele in a Zimbabwean cohort of HIV-1-infected adults. AIDS 21: 2283–2291.
[14]
Marzocchetti A, Schwarz J, Di Giambenedetto S, Colafigli M, Bracciale L, et al. (2011) The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy. AIDS Res Hum Retroviruses 27: 1299–1309. doi: 10.1089/aid.2010.0172
[15]
Brinkman BM, Keet IP, Miedema F, Verweij CL, Klein MR (1997) Polymorphisms within the human tumor necrosis factor-alpha promoter region in human immunodeficiency virus type 1-seropositive persons. J Infect Dis 175: 188–190. doi: 10.1093/infdis/175.1.188
[16]
Sachdeva N, Sehgal S, Arora SK (2005) Frequency of drug-resistant variants of HIV-1 coexistent with wild-type in treatment-naive patients of India. MedGenMed 7: 68. doi: 10.1186/1758-2652-7-3-68
[17]
Barker E, Mackewicz CE, Reyes-Teran G, Sato A, Stranford SA, et al. (1998) Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. Blood 92: 3105–3114.
[18]
Jang WH, Yang YI, Yea SS, Lee YJ, Chun JH, et al. (2001) The -238 tumor necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers. Cancer Lett 166: 41–46. doi: 10.1016/s0304-3835(01)00438-4
[19]
Veloso S, Olona M, Garcia F, Domingo P, Alonso-Villaverde C, et al. (2010) Effect of TNF-alpha genetic variants and CCR5 Delta 32 on the vulnerability to HIV-1 infection and disease progression in Caucasian Spaniards. BMC Med Genet 11: 63.
[20]
Sternfeld T, Tischleder A, Schuster M, Bogner JR (2009) Mitochondrial membrane potential and apoptosis of blood mononuclear cells in untreated HIV-1 infected patients. HIV Med 10: 512–519. doi: 10.1111/j.1468-1293.2009.00723.x
[21]
Tayebi S, Mohamadkhani A (2012) The TNF-alpha -308 Promoter Gene Polymorphism and Chronic HBV Infection. Hepat Res Treat 2012: 493219. doi: 10.1155/2012/493219
[22]
Barrett S, Collins M, Kenny C, Ryan E, Keane CO, et al. (2003) Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol 71: 212–218. doi: 10.1002/jmv.10472
[23]
Cabrera M, Shaw MA, Sharples C, Williams H, Castes M, et al. (1995) Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J Exp Med 182: 1259–1264. doi: 10.1084/jem.182.5.1259
[24]
Sharma S, Rathored J, Ghosh B, Sharma SK (2010) Genetic polymorphisms in TNF genes and tuberculosis in North Indians. BMC Infect Dis 10: 165. doi: 10.1186/1471-2334-10-165
[25]
Kumar N, Kaur G, Tandon N, Mehra N (2012) Tumor necrosis factor-associated susceptibility to type 1 diabetes is caused by linkage disequilibrium with HLA-DR3 haplotypes. Hum Immunol 73: 566–573. doi: 10.1016/j.humimm.2012.01.012
[26]
Werth VP, Callen JP, Ang G, Sullivan KE (2002) Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis. J Invest Dermatol 119: 617–620. doi: 10.1046/j.1523-1747.2002.01869.x
[27]
Chaudhari DV, Chavan VR, Kerkar SC, Mehta PR, Mania-Pramanik J (2013) Polymorphisms in major cytokine genes: a study among human immunodeficiency Virus-1 serodiscordant couples in Mumbai, India. Indian J Med Microbiol 31: 166–172.
[28]
Fernandez-Mestre MT, Gendzekhadze K, Rivas-Vetencourt P, Layrisse Z (2004) TNF-alpha-308A allele, a possible severity risk factor of hemorrhagic manifestation in dengue fever patients. Tissue Antigens 64: 469–472. doi: 10.1111/j.1399-0039.2004.00304.x
[29]
Alfano M, Poli G (2005) Role of cytokines and chemokines in the regulation of innate immunity and HIV infection. Mol Immunol 42: 161–182. doi: 10.1016/j.molimm.2004.06.016
[30]
Fernandez-Ortega C, Dubed M, Ramos Y, Navea L, Alvarez G, et al. (2004) Non-induced leukocyte extract reduces HIV replication and TNF secretion. Biochem Biophys Res Commun 325: 1075–1081. doi: 10.1016/j.bbrc.2004.10.142
[31]
Leghmari K, Bennasser Y, Tkaczuk J, Bahraoui E (2008) HIV-1 Tat protein induces IL-10 production by an alternative TNF-alpha-independent pathway in monocytes: role of PKC-delta and p38 MAP kinase. Cell Immunol 253: 45–53. doi: 10.1016/j.cellimm.2008.04.015
[32]
Merino AM, Zhang K, Kaslow RA, Aissani B (2013) Structure of tumor necrosis factor-alpha haploblocks in European populations. Immunogenetics 65: 543–552. doi: 10.1007/s00251-013-0700-2
[33]
Simpson PD, Moysi E, Wicks K, Sudan K, Rowland-Jones SL, et al. (2012) Functional differences exist between TNFalpha promoters encoding the common -237G SNP and the rarer HLA-B*5701-linked A variant. PLoS One 7: e40100. doi: 10.1371/journal.pone.0040100
